A double-blind, randomized, placebo-controlled, multicenter study investigating the efficacy and tolerability of angeliq(drospirenon2mg and estradiol 1mg) in postmenopausal korean women with vasomotor symptoms over 3, 28 day treatment cycle.

Trial Profile

A double-blind, randomized, placebo-controlled, multicenter study investigating the efficacy and tolerability of angeliq(drospirenon2mg and estradiol 1mg) in postmenopausal korean women with vasomotor symptoms over 3, 28 day treatment cycle.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Estradiol/drospirenone (Primary)
  • Indications Hot flashes
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 03 Mar 2009 Actual patient number (72) added as reported by ClinicalTrials.gov.
    • 03 Mar 2009 Bayer Schering Pharma added as trial affiliate as reported by ClinicalTrials.gov.
    • 22 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top